Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy.

被引：0
|
作者：
Takahashi, Chiaki [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa, Japan
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1001
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CDK4/6 inhibitor combination therapy for the treatment of RB1-intact HCC
    Sheng, Jindan
    Kohno, Susumu
    Takahashi, Chiaki
    CANCER SCIENCE, 2022, 113 : 555 - 555
  • [2] Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
    O'Brien, Neil A.
    McDermott, Martina S.
    O'Boyle, Brendan M.
    Hilf, Justin A.
    Loson, Oliver
    Chau, Kevin
    Jia, Weiping
    Kamranpour, Naeimeh
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Glaspy, John A.
    Stoltz, Brian M.
    Slamon, Dennis J.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive Cancers
    De Forni, Davide
    Poddesu, Barbara
    Cugia, Giulia
    Bonelli, Mara
    Galetti, Maricla
    Petronini, Piergiorgio
    Lagace, Lisette
    Chafouleas, James
    Lori, Franco
    CURRENT MEDICINAL CHEMISTRY, 2025, 32 (07) : 1333 - 1354
  • [5] TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML
    Uras, I.
    Valent, P.
    Sexl, V.
    HAEMATOLOGICA, 2017, 102 : 207 - 208
  • [6] Improving immunotherapy with a combination of CDK4/6 inhibitor
    Yoshida, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S208 - S208
  • [7] Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy.
    Torres-Guzman, Raquel
    Ganado, Maria Patricia
    Perez, Cecila Mur
    Marugan, Carlos
    Baquero, Carmen
    Yang, Yanzhu
    Du, Jian
    de Dios, Alfonso
    Puig, Oscar
    Lallena, Maria Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report
    Maimon, Ofra
    Nisman, Benjamin
    Broier, Shani
    Ben-david, Inna
    Kuznetz, Anna
    Gelfand, Yael
    Mizrahi, Avital
    Prus, Eugenia
    Fuchs, Inbal
    Lotem, Michal
    Popovtzer, Aron
    Khutsurauli, Salome
    Meirovitz, Amichay
    Nechushtan, Hovav
    Peretz, Tamar
    ANTICANCER RESEARCH, 2024, 44 (08) : 3543 - 3550
  • [9] Novel combination of AR inhibitor and CDK4/6 inhibitor, MEK inhibitor in non-HR positive breast cancers
    Lim, B.
    Lee, L.
    Pearson, T.
    Liu, H.
    Hwang, M.
    Choi, K.
    Tripathy, D.
    Ueno, N. T.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S14 - S15
  • [10] RB1 SUPPRESSION IS RESPONSIBLE FOR ACQUIRED CDK4/6 INHIBITOR RESISTANCE IN GLIOBLASTOMA
    James, C. David
    Lu, Yu-Jen
    Ozawa, Tomoko
    Prados, Michael D.
    Waldman, Todd
    NEURO-ONCOLOGY, 2014, 16
12345